T2 Biosystems Inc. (NASDAQ: TTOO) is 24.19% higher on its value in year-to-date trading and has touched a low of $0.45 and a high of $3.79 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The TTOO stock was last observed hovering at around $1.61 in the last trading session, with the day’s loss setting it -0.07% off its average median price target of $3.00 for the next 12 months. It is also 56.0% off the consensus price target high of $3.50 offered by 5 analysts, but current levels are 6.67% higher than the price target low of $1.65 for the same period.
Currently trading at $1.54, the stock is -16.01% and -31.40% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 3.79 million and changing -4.35% at the moment leaves the stock -2.75% off its SMA200. TTOO registered 138.39% gain for a year compared to 6-month gain of 30.51%. The firm has a 50-day simple moving average (SMA 50) of $2.2888 and a 200-day simple moving average (SMA200) of $1.6185.
The stock witnessed a -32.75% loss in the last 1 month and extending the period to 3 months gives it a 32.76%, and is -13.48% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 10.42% over the week and 12.74% over the month.
T2 Biosystems Inc. (TTOO) has around 151 employees, a market worth around $237.98M and $18.10M in sales. Distance from 52-week low is 242.22% and -59.37% from its 52-week high. The company has generated returns on investments over the last 12 months (-584.90%).
T2 Biosystems Inc. (TTOO) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for T2 Biosystems Inc. (TTOO) is a “Buy”. 5 analysts offering their recommendations for the stock have an average rating of 1.60, where 1 rate it as a Hold and 0 think it is a “Overweight”. 4 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
T2 Biosystems Inc. is expected to release its quarterly report on 05/05/2021 and quarterly earnings per share for the current quarter are estimated at -$0.07 with sales reaching $6.44M over the same period.The EPS is expected to shrink by -2.80% this year, but quarterly earnings will post 38.30% year-over-year. Quarterly sales are estimated to grow 144.90% in year-over-year returns.
T2 Biosystems Inc. (TTOO) Top Institutional Holders
66 institutions hold shares in T2 Biosystems Inc. (TTOO), with 7.12M shares held by insiders accounting for 4.81% while institutional investors hold 13.36% of the company’s shares. The shares outstanding are 147.79M, and float is at 140.78M with Short Float at 7.27%. Institutions hold 12.71% of the Float.
The top institutional shareholder in the company is Vanguard Group, Inc. (The) with over 6.19 million shares valued at $7.67 million. The investor’s holdings represent 4.18% of the TTOO Shares outstanding. As of Dec 30, 2020, the second largest holder is Goldman Sachs Group, Inc. with 4.36 million shares valued at $5.4 million to account for 2.95% of the shares outstanding. The other top investors are Blackrock Inc. which holds 2.2 million shares representing 1.49% and valued at over $2.73 million, while Millennium Management LLC holds 0.89% of the shares totaling 1.32 million with a market value of $1.63 million.
T2 Biosystems Inc. (TTOO) Insider Activity
A total of 14 insider transactions have happened at T2 Biosystems Inc. (TTOO) in the last six months, with sales accounting for 6 and purchases happening 8 times. The most recent transaction is an insider sale by Gibbs Michael Terrence ,the company’sGeneral Counsel. SEC filings show that Gibbs Michael Terrence sold 8,758 shares of the company’s common stock on Mar 25 at a price of $1.56 per share for a total of $13662.0. Following the sale, the insider now owns 73256.0 shares.
T2 Biosystems Inc. disclosed in a document filed with the SEC on Mar 17 that Pare Anthony (Chief Commercial Officer) sold a total of 9,620 shares of the company’s common stock. The trade occurred on Mar 17 and was made at $1.84 per share for $17701.0. Following the transaction, the insider now directly holds 31612.0 shares of the TTOO stock.
Still, SEC filings show that on Mar 17, Barclay Alec (Chief Operations Officer) disposed off 12,494 shares at an average price of $1.86 for $23239.0. The insider now directly holds 74,420 shares of T2 Biosystems Inc. (TTOO).